Cargando…

Predicting high risk of exacerbations in bronchiectasis: the E-FACED score

BACKGROUND: Although the FACED score has demonstrated a great prognostic capacity in bronchiectasis, it does not include the number or severity of exacerbations as a separate variable, which is important in the natural history of these patients. OBJECTIVE: Construction and external validation of a n...

Descripción completa

Detalles Bibliográficos
Autores principales: Martinez-Garcia, MA, Athanazio, RA, Girón, R, Máiz-Carro, L, de la Rosa, D, Olveira, C, de Gracia, J, Vendrell, M, Prados-Sánchez, C, Gramblicka, G, Corso Pereira, M, Lundgren, FL, Fernandes De Figueiredo, M, Arancibia, F, Rached, SZ
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5279836/
https://www.ncbi.nlm.nih.gov/pubmed/28182132
http://dx.doi.org/10.2147/COPD.S121943
_version_ 1782502854041272320
author Martinez-Garcia, MA
Athanazio, RA
Girón, R
Máiz-Carro, L
de la Rosa, D
Olveira, C
de Gracia, J
Vendrell, M
Prados-Sánchez, C
Gramblicka, G
Corso Pereira, M
Lundgren, FL
Fernandes De Figueiredo, M
Arancibia, F
Rached, SZ
author_facet Martinez-Garcia, MA
Athanazio, RA
Girón, R
Máiz-Carro, L
de la Rosa, D
Olveira, C
de Gracia, J
Vendrell, M
Prados-Sánchez, C
Gramblicka, G
Corso Pereira, M
Lundgren, FL
Fernandes De Figueiredo, M
Arancibia, F
Rached, SZ
author_sort Martinez-Garcia, MA
collection PubMed
description BACKGROUND: Although the FACED score has demonstrated a great prognostic capacity in bronchiectasis, it does not include the number or severity of exacerbations as a separate variable, which is important in the natural history of these patients. OBJECTIVE: Construction and external validation of a new index, the E-FACED, to evaluate the predictive capacity of exacerbations and mortality. METHODS: The new score was constructed on the basis of the complete cohort for the construction of the original FACED score, while the external validation was undertaken with six cohorts from three countries (Brazil, Argentina, and Chile). The main outcome was the number of annual exacerbations/hospitalizations, with all-cause and respiratory-related deaths as the secondary outcomes. A statistical evaluation comprised the relative weight and ideal cut-off point for the number or severity of the exacerbations and was incorporated into the FACED score (E-FACED). The results obtained after the application of FACED and E-FACED were compared in both the cohorts. RESULTS: A total of 1,470 patients with bronchiectasis (819 from the construction cohorts and 651 from the external validation cohorts) were followed up for 5 years after diagnosis. The best cut-off point was at least two exacerbations in the previous year (two additional points), meaning that the E-FACED has nine points of growing severity. E-FACED presented an excellent prognostic capacity for exacerbations (areas under the receiver operating characteristic curve: 0.82 for at least two exacerbations in 1 year and 0.87 for at least one hospitalization in 1 year) that was statistically better than that of the FACED score (0.72 and 0.78, P<0.05, respectively). The predictive capacities for all-cause and respiratory mortality were 0.87 and 0.86, respectively, with both being similar to those of the FACED. CONCLUSION: E-FACED score significantly increases the FACED capacity to predict future yearly exacerbations while maintaining the score’s simplicity and prognostic capacity for death.
format Online
Article
Text
id pubmed-5279836
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-52798362017-02-08 Predicting high risk of exacerbations in bronchiectasis: the E-FACED score Martinez-Garcia, MA Athanazio, RA Girón, R Máiz-Carro, L de la Rosa, D Olveira, C de Gracia, J Vendrell, M Prados-Sánchez, C Gramblicka, G Corso Pereira, M Lundgren, FL Fernandes De Figueiredo, M Arancibia, F Rached, SZ Int J Chron Obstruct Pulmon Dis Original Research BACKGROUND: Although the FACED score has demonstrated a great prognostic capacity in bronchiectasis, it does not include the number or severity of exacerbations as a separate variable, which is important in the natural history of these patients. OBJECTIVE: Construction and external validation of a new index, the E-FACED, to evaluate the predictive capacity of exacerbations and mortality. METHODS: The new score was constructed on the basis of the complete cohort for the construction of the original FACED score, while the external validation was undertaken with six cohorts from three countries (Brazil, Argentina, and Chile). The main outcome was the number of annual exacerbations/hospitalizations, with all-cause and respiratory-related deaths as the secondary outcomes. A statistical evaluation comprised the relative weight and ideal cut-off point for the number or severity of the exacerbations and was incorporated into the FACED score (E-FACED). The results obtained after the application of FACED and E-FACED were compared in both the cohorts. RESULTS: A total of 1,470 patients with bronchiectasis (819 from the construction cohorts and 651 from the external validation cohorts) were followed up for 5 years after diagnosis. The best cut-off point was at least two exacerbations in the previous year (two additional points), meaning that the E-FACED has nine points of growing severity. E-FACED presented an excellent prognostic capacity for exacerbations (areas under the receiver operating characteristic curve: 0.82 for at least two exacerbations in 1 year and 0.87 for at least one hospitalization in 1 year) that was statistically better than that of the FACED score (0.72 and 0.78, P<0.05, respectively). The predictive capacities for all-cause and respiratory mortality were 0.87 and 0.86, respectively, with both being similar to those of the FACED. CONCLUSION: E-FACED score significantly increases the FACED capacity to predict future yearly exacerbations while maintaining the score’s simplicity and prognostic capacity for death. Dove Medical Press 2017-01-18 /pmc/articles/PMC5279836/ /pubmed/28182132 http://dx.doi.org/10.2147/COPD.S121943 Text en © 2017 Martinez-Garcia et al. This work is published and licensed by Dove Medical Press Limited The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.
spellingShingle Original Research
Martinez-Garcia, MA
Athanazio, RA
Girón, R
Máiz-Carro, L
de la Rosa, D
Olveira, C
de Gracia, J
Vendrell, M
Prados-Sánchez, C
Gramblicka, G
Corso Pereira, M
Lundgren, FL
Fernandes De Figueiredo, M
Arancibia, F
Rached, SZ
Predicting high risk of exacerbations in bronchiectasis: the E-FACED score
title Predicting high risk of exacerbations in bronchiectasis: the E-FACED score
title_full Predicting high risk of exacerbations in bronchiectasis: the E-FACED score
title_fullStr Predicting high risk of exacerbations in bronchiectasis: the E-FACED score
title_full_unstemmed Predicting high risk of exacerbations in bronchiectasis: the E-FACED score
title_short Predicting high risk of exacerbations in bronchiectasis: the E-FACED score
title_sort predicting high risk of exacerbations in bronchiectasis: the e-faced score
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5279836/
https://www.ncbi.nlm.nih.gov/pubmed/28182132
http://dx.doi.org/10.2147/COPD.S121943
work_keys_str_mv AT martinezgarciama predictinghighriskofexacerbationsinbronchiectasistheefacedscore
AT athanaziora predictinghighriskofexacerbationsinbronchiectasistheefacedscore
AT gironr predictinghighriskofexacerbationsinbronchiectasistheefacedscore
AT maizcarrol predictinghighriskofexacerbationsinbronchiectasistheefacedscore
AT delarosad predictinghighriskofexacerbationsinbronchiectasistheefacedscore
AT olveirac predictinghighriskofexacerbationsinbronchiectasistheefacedscore
AT degraciaj predictinghighriskofexacerbationsinbronchiectasistheefacedscore
AT vendrellm predictinghighriskofexacerbationsinbronchiectasistheefacedscore
AT pradossanchezc predictinghighriskofexacerbationsinbronchiectasistheefacedscore
AT gramblickag predictinghighriskofexacerbationsinbronchiectasistheefacedscore
AT corsopereiram predictinghighriskofexacerbationsinbronchiectasistheefacedscore
AT lundgrenfl predictinghighriskofexacerbationsinbronchiectasistheefacedscore
AT fernandesdefigueiredom predictinghighriskofexacerbationsinbronchiectasistheefacedscore
AT arancibiaf predictinghighriskofexacerbationsinbronchiectasistheefacedscore
AT rachedsz predictinghighriskofexacerbationsinbronchiectasistheefacedscore